ATE415396T1 - Pyrazine derivate als tyrosin kinase modulatoren - Google Patents

Pyrazine derivate als tyrosin kinase modulatoren

Info

Publication number
ATE415396T1
ATE415396T1 AT01975243T AT01975243T ATE415396T1 AT E415396 T1 ATE415396 T1 AT E415396T1 AT 01975243 T AT01975243 T AT 01975243T AT 01975243 T AT01975243 T AT 01975243T AT E415396 T1 ATE415396 T1 AT E415396T1
Authority
AT
Austria
Prior art keywords
tyrosine kinase
pyrazine derivatives
kinase modulators
modulators
pyrazine
Prior art date
Application number
AT01975243T
Other languages
English (en)
Inventor
Gee Kuo
Peter Connolly
Catherine Prouty
Alan Deangelis
Aihua Wang
Linda Jolliffe
Steve Middleton
Stuart Emanuel
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22879359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE415396(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE415396T1 publication Critical patent/ATE415396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01975243T 2000-09-20 2001-09-19 Pyrazine derivate als tyrosin kinase modulatoren ATE415396T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23396800P 2000-09-20 2000-09-20

Publications (1)

Publication Number Publication Date
ATE415396T1 true ATE415396T1 (de) 2008-12-15

Family

ID=22879359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01975243T ATE415396T1 (de) 2000-09-20 2001-09-19 Pyrazine derivate als tyrosin kinase modulatoren

Country Status (14)

Country Link
US (1) US6710048B2 (de)
EP (1) EP1330452B1 (de)
JP (1) JP2004523474A (de)
AR (1) AR035494A1 (de)
AT (1) ATE415396T1 (de)
AU (1) AU9458401A (de)
CA (1) CA2423050A1 (de)
DE (1) DE60136731D1 (de)
DK (1) DK1330452T3 (de)
ES (1) ES2315308T3 (de)
HK (1) HK1054393B (de)
PT (1) PT1330452E (de)
TW (1) TWI254711B (de)
WO (1) WO2002024681A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (de) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Kondensierte heterozyklische Succinimid-Verbindungen und Analoga daraus, Modulatoren der nuklearen Hormonrezeptorfunktion
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7087636B2 (en) * 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1501514B1 (de) * 2002-05-03 2012-12-19 Exelixis, Inc. Proteinkinasemodulatoren und verfahren zur derer anwendung
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
AUPS251402A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Kinase inhibitors
AU2003249369A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
GB0215775D0 (en) * 2002-07-06 2002-08-14 Astex Technology Ltd Pharmaceutical compounds
CA2501719C (en) * 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
US8030336B2 (en) * 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
US20040121968A1 (en) * 2002-12-23 2004-06-24 Alexander Ljubimov Antiangiogenesis by inhibiting protein kinase CK2 activity
DK1603570T5 (da) * 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005003101A2 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
EP1670794A2 (de) 2003-09-30 2006-06-21 Amgen Inc. Vanilloidrezeptorliganden und deren verwendung bei behandlungen
AU2004295050A1 (en) * 2003-11-24 2005-06-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
ATE481134T1 (de) 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
WO2006051311A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
GB0500226D0 (en) * 2005-01-07 2005-02-16 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
EP1917244A2 (de) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
US8466154B2 (en) 2006-10-27 2013-06-18 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
CN101687839A (zh) * 2007-05-16 2010-03-31 拜尔农科股份有限公司 杀真菌剂苯基-嘧啶基-氨基衍生物
EP2203436A1 (de) * 2007-09-17 2010-07-07 Neurosearch A/S Pyrazinderivate und ihre verwendung als kaliumkanalmodulatoren
KR100898037B1 (ko) * 2007-10-05 2009-06-01 한국화학연구원 금속촉매의 커플링반응에 의한 트리알킬피라진 유도체의제조방법
WO2010000353A1 (en) 2008-06-09 2010-01-07 Sanofi-Aventis Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
NZ713361A (en) * 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
IN2012DN01273A (de) * 2009-09-04 2015-05-15 Novartis Ag
US20110185353A1 (en) * 2010-01-27 2011-07-28 Jack Matthew Mitigating Problems Arising From Incompatible Software
CN103298787A (zh) * 2010-11-17 2013-09-11 诺瓦提斯公司 3-(氨基芳基)-吡啶化合物
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
CA2840883C (en) * 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
NZ746607A (en) 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
WO2015076800A1 (en) * 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
JP6607870B2 (ja) 2014-05-13 2019-11-20 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ７０モジュレーターならびにその作製および使用方法
CN110799190B (zh) 2017-03-27 2024-04-19 卡都瑞恩医药有限公司 杂环化合物
GB201715414D0 (en) * 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
GB201715318D0 (en) 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
EP3836932A2 (de) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Verfahren zur behandlung von bauchspeicheldrüsenkrebs
JP7447098B2 (ja) 2018-09-25 2024-03-11 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド アミノピリミジン化合物
EP4182308B1 (de) 2020-07-15 2024-09-04 Chiesi Farmaceutici S.p.A. Pyridazinylaminoderivate als alk5-inhibitoren
JP7824282B2 (ja) 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用
US20250011299A1 (en) 2021-09-21 2025-01-09 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
AU2023207775A1 (en) 2022-01-11 2024-08-22 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514400A (en) * 1981-10-26 1985-04-30 William H. Rorer, Inc. Cardiotonic 5-heteroaryl-pyridone
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
EP0994875B1 (de) 1997-06-30 2004-03-10 Targacept, Inc. 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
ATE252572T1 (de) * 1998-06-30 2003-11-15 Lilly Co Eli 5-ht1f agonisten
CN1374953A (zh) * 1999-09-16 2002-10-16 田边制药株式会社 含氮的6－员芳香环化合物
PL365238A1 (en) 2000-02-16 2004-12-27 Neurogen Corporation Substituted arylpyrazines

Also Published As

Publication number Publication date
JP2004523474A (ja) 2004-08-05
US6710048B2 (en) 2004-03-23
TWI254711B (en) 2006-05-11
HK1054393B (en) 2009-08-28
WO2002024681A2 (en) 2002-03-28
CA2423050A1 (en) 2002-03-28
ES2315308T3 (es) 2009-04-01
EP1330452B1 (de) 2008-11-26
AU9458401A (en) 2002-04-02
DE60136731D1 (de) 2009-01-08
US20030060629A1 (en) 2003-03-27
WO2002024681A3 (en) 2002-06-20
HK1054393A1 (en) 2003-11-28
DK1330452T3 (da) 2009-03-16
AR035494A1 (es) 2004-06-02
PT1330452E (pt) 2009-01-22
EP1330452A2 (de) 2003-07-30

Similar Documents

Publication Publication Date Title
ATE415396T1 (de) Pyrazine derivate als tyrosin kinase modulatoren
ATE309996T1 (de) Chinolinonderivate als tyrosin-kinase inhibitoren
ATE316527T1 (de) Substituierte indolinone als tyrosinkinase inhibitoren
ATE286045T1 (de) Tyrosin kinaseinhibitoren
ATE255575T1 (de) Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
EP1161433A4 (de) Tyrosin-kinase-inhibitoren
DE60120193D1 (de) Pyrazolverbindungen als protein-kinasehemmer
DE60119777D1 (de) Pyrazolverbindungen als protein-kinasehemmer
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
CY2014034I2 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
NO20014970L (no) Cyklisk protein-tyrosin-kinase-inhibitor
IS6968A (is) Nýir týrósínkínasa tálmar
DE69511253D1 (de) Wasserlösliche 3-arylidene-2-oxindole derivate als tyrosine kinase inhibitoren
NO20024235L (no) 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer
DE60113533D1 (de) Derivate von beta-aminosäurenitrilen
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
DK1226136T3 (da) Tyrosinkinaseinhibitor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1330452

Country of ref document: EP

RZN Patent revoked